Roche Holding AG (RHHVF)
OTCMKTS · Delayed Price · Currency is USD
439.07
-9.96 (-2.22%)
At close: Mar 6, 2026
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B CHF
Revenue Growth
+1.54%
P/S Ratio
4.38
Revenue / Employee
613.62K CHF
Employees
103,249
Market Cap
350.32B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 140.12M |
| Tian'an Technology Group | 2.12M |
| Northwest Biotherapeutics | 937.00K |
| Comjoyful International Company | 564.97K |
Roche Holding AG News
- 1 hour ago - Genentech: PersevERA Breast Cancer Study Fails To Meet Primary Objective - Nasdaq
- 1 hour ago - Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study - WSJ
- 2 hours ago - Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer - Business Wire
- 2 hours ago - [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer - GlobeNewsWire
- 20 hours ago - 2 Underrated Weight Loss Stocks to Buy Now - The Motley Fool
- 1 day ago - Roche (RHHBY) Diagnostics Division Faces Tariff Challenges - GuruFocus
- 1 day ago - Roche chairman still expects diagnostics hit from US tariffs - Reuters
- 2 days ago - Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics' - CNBC